-
Drug Stocks Finally Make Their Move
Tuesday, March 29, 2011 - 1:01pm | 204(TheStreet) -- Drug stocks such as Johnson & Johnson (NYSE: JNJ) and Gilead Sciences (NASDAQ: GILD) have been beaten up in the year since the health-care reform bill was passed. That may soon change, as fund managers are pouncing on shares of undervalued companies. Over the past year, the S...
-
GSK and Valeant Receive European Authorisation for Trobalt
Tuesday, March 29, 2011 - 12:17pm | 61GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced today that the European Commission has granted marketing authorisation for Trobalt (retigabine) as an adjunctive (add-on) treatment of partial onset seizures, with or without secondary generalisation...
-
March Market Madness: Pfizer (PFE)
Tuesday, March 29, 2011 - 11:30am | 284As we mentioned earlier, this month we are going to be looking at the stocks that make up the DJIA. . Next up Pfizer (PFE). Over the last few weeks we have started a discussion of some of the more important features of our “OneSheet” stock overviews. Now we are going to present the next...
-
Sanofi-aventis Announces Statement Related to Genzyme Acquisition: Effective for $74.00 per Share
Tuesday, March 29, 2011 - 11:00am | 136Sanofi-aventis (NYSE: SNY) announced today that the registration statement relating to the Contingent Value Rights offered to Genzyme shareholders as part of sanofi-aventis' agreement to acquire Genzyme has been declared effective by the U.S. Securities and Exchange Commission. In accordance with...
-
ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor for Treatment of Antibody-Mediated Rejection
Tuesday, March 29, 2011 - 10:56am | 53ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 clinical study to evaluate the safety and efficacy of C1 Esterase Inhibitor for the treatment of acute antibody-mediated rejection (AMR) in recipients of donor-specific cross-match positive kidney transplants.
-
FDA Clears Abbott's i-STAT 1 Wireless Point of Care Testing System
Tuesday, March 29, 2011 - 9:07am | 78Abbott (NYSE: ABT) announced today it has received clearance from the U.S. Food and Drug Administration to begin marketing the i-STAT® 1 Wireless handheld, a new wireless version of the i-STAT® point of care testing system that is widely used in hospitals, emergency rooms and physicians' offices. T...
-
Abbott Labs Receives FDA Clearance For 'i-STAT 1 Wireless' Marketing (ABT)
Tuesday, March 29, 2011 - 9:03am | 20Abbott Labs Receives FDA Clearance For 'i-STAT 1' Wireless Marketing (NYSE: ABT)
-
UPDATE: J.P. Morgan Raises PT on Valeant Pharmaceuticals to $46 (VRX)
Tuesday, March 29, 2011 - 8:30am | 122J.P. Morgan is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), raising its PT from $44 to $46. In a note to clients, J.P. Morgan writes, "We remain Overweight on VRX shares. Through its business development growth model and favorable tax structure compared to its competitors, we...
-
Catalyst Announces Commencement of CPP-109 Investigator-Sponsored Study in Cocaine and Alcohol Co-Dependent Patients
Tuesday, March 29, 2011 - 8:11am | 124Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that researchers at the University of Pennsylvania have commenced a 60 subject, double-blind, placebo-controlled, investigator-sponsored study to evaluate the use of CPP-109 (vigabatrin) for the treatment of patients addicted to...
-
Atelvia Sales Down 3.93%, Oppenheimer Reports (WCRX)
Tuesday, March 29, 2011 - 8:00am | 79Oppenheimer reports that for the week ended March 18, 2011, weekly sales of Atelvia – from Warner Chilcott's (NASDAQ: WCRX) – were $0.5M, down 3.93% week/week. “Atelvia weekly sales are averaging $0.3M during 1Q'11,” Oppenheimer writes. “Weekly NRx of Atelvia were 2,774, down 2.08% week/week....
-
Jefferies Reiterating Buy On Optimer Pharm. (OPTR)
Tuesday, March 29, 2011 - 7:27am | 198Jefferies & Co. is reiterating its Buy rating and $17 price target on shares of Optimer Pharm. (NASDAQ: OPTR). In a note to clients, Jefferies writes, "For lead drug fidaxomicin, FDA's AdComm panel and PDUFA date are set for April 5 and May 30, respectively. While the Street sentiment is...
-
Mad Money Lightning Round: Cramer Likes Gentex, Micron Technology (AES, CHS, ASNA, BTU, WLT, LLY, LYG, GNTX, MSFT, INTC, CSCO, MU)
Tuesday, March 29, 2011 - 1:22am | 315On CNBC's Mad Money, Jim Cramer said during the Lightning Round that AES Corp (NYSE: AES) is a “great play on the growth of electricity. That's an inexpensive stock." He likes Chico's (NYSE: CHS). He added, “That's a nice turn over there. It reminds me of Ascena Retail Group (NASDAQ: ASNA)."...
-
Inflation is on the Brain 03-28-2011
Monday, March 28, 2011 - 7:02pm | 864Cusick's Corner Inflation is on the brain and with the Hawks circling, this market needs leadership to arise before any real money is going to work. With that said, we may have this choppy action until the jobs data comes in at the end of this week. The Consumer Confidence Number will be a big one...
-
Trade Ideas for Tuesday, March 29
Monday, March 28, 2011 - 6:03pm | 1462( click to enlarge ) Tellabs, Inc. (NASDAQ:TLAB) starts showing ‘buy' signals again.The stock closed above its 20-day moving average for the first time since January, which is a very bullish sign. Although the stock didn't perform well this year, we start to see now some signals of rebound...
-
Is Approval of Bristol-Myers Squibb's Yervoy Start of New Chapter at FDA?
Monday, March 28, 2011 - 1:08pm | 903By David Miller Last week, I wrote in Why FDA May Not Approve Bristol-Myers Squibb's Ipilimumab how I believed the most likely outcome of Bristol-Myers Squibb's (BMY) application for ipilimumab (trade name Yervoy) would be a delay in the decision by the FDA. Instead, FDA oncology division director...